Vera Therapeutics Inc.
(VERA)
undefined
undefined%
At close: undefined
43.22
0.16%
After-hours Jan 03, 2025, 04:00 PM EST
Company Description
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States.
Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy.
It is also developing MAU868, a monoclonal antibody for the treatment of BK viremia infections and is under Phase 2 clinical trial.
The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020.
Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.
Vera Therapeutics Inc.
| Country | United States |
| IPO Date | May 14, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 82 |
| CEO | Dr. Marshall W. Fordyce M.D. |
Contact Details
Address: 8000 Marina Boulevard Brisbane, California United States | |
| Website | https://veratx.com |
Stock Details
| Ticker Symbol | VERA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001831828 |
| CUSIP Number | 92337R101 |
| ISIN Number | US92337R1014 |
| Employer ID | 81-2744449 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Marshall W. Fordyce M.D. | Founder, President, Chief Executive Officer & Director |
| Jason S Carter | Chief Legal Officer |
| Sean P. Grant M.B.A. | Chief Financial Officer |
| David L. Johnson M.B.A. | Chief Opearating Officer |
| Dr. Allen Ebens B.Sc., Ph.D. | Executive Vice President of Research |
| Joseph R. Young M.B.A. | Senior Vice President of Finance & Chief Accounting Officer |
| Julien E. Capers J.D. | Senior Vice President of Legal |
| Kelly Rauber | Senior Vice President of Human Resources |
| Lauren Frenz M.B.A. | Chief Business Officer |
| Tom Doan | Senior Vice President of Development Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 20, 2024 | 4 | Filing |
| Dec 13, 2024 | 4 | Filing |
| Nov 27, 2024 | 4 | Filing |
| Nov 20, 2024 | 4 | Filing |
| Nov 20, 2024 | 3 | Filing |
| Nov 15, 2024 | 4 | Filing |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |